Search results
Results from the WOW.Com Content Network
Isomyosamine, also known as MyMD-1 or MYMD-1, is a synthetic derivative of tobacco plant alkaloids being developed as a metabolic- and immunomodulator by MyMD Pharmaceuticals. To date, isomyosamine has been shown to suppress the production of IFN-γ , IL-2 , IL-10 , and TNF-α , and decrease the severity of experimental thyroiditis in a murine ...
Expert Opinion on Therapeutic Patents is a monthly peer-reviewed medical journal covering pharmaceutical patent information across all therapy areas. Each review includes an "expert opinion" section, in which authors provide their personal view on the current status and future direction of the research discussed.
The publication does not include drugs on the market approved only on the basis of safety (covered by the ongoing Drug Efficacy Study Implementation [DESI] review [e.g., Donnatal Tablets and Librax Capsules] or pre-1938 drugs [e.g., Phenobarbital Tablets]).
The office's Patent Trial and Appeal Board denied the requests by Mylan Pharmaceuticals, which is owned by Viatris, to review the validity of the Wegovy and Ozempic patents.
Hatch-Waxman Drug Price Competition and Patent Term Restoration Act encouraged generic pharmaceutical manufacturers to challenge the validity of wrongfully issued pharmaceutical patents. 1999. US Congress established an inter partes reexamination to allow the USPTO to review validity of issued patents with participation of third party challengers.
An inter partes review is used to challenge the patentability of one or more claims in a U.S. patent only on a ground that could be raised under 35 U.S.C. §§ 102 or 103 (non-obviousness), and only on the basis of prior art consisting of patents or printed publications. [3]
In response to these criticisms, one review concluded that less than 5 percent of medicines on the World Health Organization's list of essential drugs are under patent. [36] Also, the pharmaceutical industry has contributed US$2 billion for healthcare in developing countries, providing HIV/AIDS drugs at lower cost or even free of charge in ...
A dispute over patents for similar chemical processes. Perfect Web Technologies, Inc. v. InfoUSA, Inc. - CAFC, 2009. Applied KSR-style obviousness analysis to invalidate a patent. Abbott v. Sandoz - Pharmaceutical patent case involving differentiation of products by process.